Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 12/20 | 0.62 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.62 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.57 |
| ▸ | AXL | P30530 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | CPT1A | P50416 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31753965 | 1.00 | NR4A2 (0.62) | NR4A2CREBBPMAP2K1AXLKDM4E | |
| SCHEMBL1763120 | 0.85 | CYP2D6 (0.45) | NR4A2CREBBPMAP2K1AXLHASPIN | |
| SCHEMBL22299985 | 0.84 | NR4A2 (0.43) | NR4A2CREBBPMAP2K1AXLHASPIN | |
| SCHEMBL1006364 | 0.84 | KDM5A (0.54) | NR4A2CREBBPKDM4EALDH1A1HASPIN | |
| SCHEMBL3217902 | 0.82 | HASPIN (0.64) | KDM4EHASPINGSK3BDYRK1ACPT1A | |
| SCHEMBL30924488 | 0.82 | HASPIN (0.64) | KDM4EHASPINGSK3BDYRK1ACPT1A | |
| SCHEMBL30101234 | 0.82 | DYRK1A (0.51) | KDM4EALDH1A1HASPINGSK3BDYRK1A | |
| SCHEMBL2052704 | 0.82 | DYRK1A (0.51) | KDM4EALDH1A1HASPINGSK3BDYRK1A | |
| SCHEMBL22644105 | 0.80 | MEN1 (0.73) | NR4A2CREBBPMAP2K1AXLKDM4E | |
| SCHEMBL22558932 | 0.80 | HASPIN (0.42) | NR4A2CREBBPHASPINGSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745971-B | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-115745971-A | PARP7 inhibitor and application thereof | 重庆华森制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| EP-2812001-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| WO-2013120104-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-08-15 | — | — | WO | disclosed |
| EP-2519520-A1 | [4-(3-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLOPYRIDINYL)-METHANONE DERIVATIVES AS TRYPTASE INHIBITORS | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| CN-102770431-A | [4[4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl ] - (1H-pyrrolopyridin-yl) -methanone and its synthesis | SANOFI SA | 2012-11-07 | — | — | CN | disclosed |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-8148413-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2011078984-A1 | [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011078984-A1 | [4[4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7812043-B2 | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | disclosed |
| EP-1689392-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049019-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885CREBBP 3960/4885MAP2K1 958/4885 |
| US-20070027140-A1 | N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes | GALK1, GCKR, GCK | NR4A2 3136/4885CREBBP 692/4885MAP2K1 337/4885 |
| US-20110082144-A1 | N-HETEROARYL INDOLE CARBOXAMIDES AND ANALOGUES THEREOF, FOR USE AS GLUCOKINASE ACTIVATORS IN THE TREATMENT OF DIABETES | GCKR, GCK, GALK1 | NR4A2 1634/4885CREBBP 780/4885MAP2K1 614/4885 |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NR4A2 2024/4885CREBBP 607/4885MAP2K1 4684/4885 |
| US-20120245199-A1 | [4 [4-(AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(1H-PYRROLO-PYRIDIN-YL)-METHANONES AND SYNTHESIS THEREOF | CMA1, TPSB2, TPH1 | NR4A2 2539/4885CREBBP 2807/4885MAP2K1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.